AN INDIAN SCIENTIST’S BOLD NEW FRONTIER: A WIRELESS IMPLANT OFFERS HOPE FOR DIABETES CONTROL WITHOUT DRUGS OR INSULIN
October 23, 2026
An Indian scientist working in Switzerland has helped develop an experimental implant designed to control blood glucose without relying on external insulin or medication, opening a promising new avenue in diabetes research. The wireless device, developed by Debasis Maity and his colleagues at ETH Zurich, has demonstrated encouraging results in laboratory mice, although substantial research remains necessary before it can be tested in humans.
The implant reportedly lowered blood glucose levels in diabetic mice within approximately 90 minutes. During six weeks of treatment, researchers also observed reductions in body weight and triglyceride levels, without detecting adverse effects in the experimental animals. The findings represent an early proof of concept rather than an established treatment for people living with diabetes.
The device is implanted beneath the skin and is designed to work alongside a continuous glucose monitoring system connected through a smartphone. When blood sugar rises above a predetermined threshold, the system activates electrically, enabling the device to remove excess glucose at a controllable rate. As glucose levels approach the desired range, the process can be adjusted or stopped.
At the centre of the technology is an electrocatalyst made from tiny platinum-decorated gold particles embedded in a graphite base. When electrically activated, the catalyst converts glucose into gluconate, a compound that is rapidly excreted through the kidneys. By regulating the electrical activation, researchers aim to control the rate at which excess glucose is removed from the body.
The implant's casing measures approximately 26 millimetres by 14 millimetres by 5 millimetres. However, the research team still needs to miniaturise the technology further and integrate it with an appropriate power source, potentially using wireless charging, alongside continuous glucose monitoring.
Maity, a postdoctoral researcher at ETH Zurich, emphasised that the experiments have so far been conducted in laboratory mice. The team must refine the device and reduce its size before considering human trials. The research also demonstrated glucose clearance in laboratory experiments involving approximately five litres of liquid, comparable to the typical blood volume of an adult, although the catalyst used in those experiments was considerably larger than the intended implant.
The development is particularly significant given the global burden of diabetes. The International Diabetes Federation's 2025 Atlas estimated that nearly 590 million adults worldwide, including more than 90 million in India, were living with the condition. Existing treatments frequently involve long-term medication and, for many patients, insulin, while treatment-related side effects, affordability and adherence can present continuing challenges.
Ambrish Mithal, chair of endocrinology and diabetology at the Max Healthcare group in New Delhi, described the concept as highly novel while cautioning that results achieved in laboratory mice do not necessarily translate into equivalent outcomes in humans.
Maity, who graduated from Ramakrishna Mission Vivekananda Centenary College in Calcutta before earning a doctorate from Bharathiar University in Coimbatore, joined ETH Zurich six years ago and has worked on implant technologies intended to control metabolic disorders.
The findings, scheduled for publication in the scientific journal Science, point towards a possible drug-free approach to glucose management. Nevertheless, the implant is not currently an approved alternative to established diabetes treatments. Its effectiveness, long-term safety and suitability for human use remain to be demonstrated through further research and clinical trials.
